Skip to main content
. 2018 Jan 19;8(4):471–481. doi: 10.1002/alr.22084

Table 1.

Patient baseline demographic and clinical characteristics*

Variable Treatment (n = 201) Control (n = 99)
Age (years) 50.5 ± 12.9 47.9 ± 12.4
Male subjects, n (%) 127 (63.2) 56 (56.6)
Race, n (%)
White 164 (81.6) 80 (80.8)
Black 27 (13.4) 13 (13.1)
Asian 4 (2.0) 4 (4.0)
Other 6 (3.0) 2 (2.0)
CRS symptoms despite ongoing use of INCS, n (%)
Nasal obstruction/blockage 185 (92.0) 90 (90.9)
Postnasal discharge 182 (90.5) 83 (83.8)
Altered sense of smell/taste 174 (86.6) 89 (89.9)
Facial pain/pressure/fullness 77 (38.3) 44 (44.4)
ESS history, n (%)
Number of prior ESS
1 83 (41.3) 41 (41.4)
2 57 (28.4) 36 (36.4)
3 32 (15.9) 7 (7.1)
≥4 29 (14.4) 15 (15.2)
Indicated for repeat ESS 201 (100) 99 (100)
Medical history, n (%)a
Allergic rhinitis 155 (77.1) 79 (79.8)
Mild 52 (25.9) 23 (23.2)
Moderate 78 (38.8) 43 (43.4)
Severe 25 (12.4) 13 (13.1)
Asthma 148 (73.6) 61 (61.6)
Mild 84 (41.8) 31 (31.3)
Moderate 56 (27.9) 26 (26.3)
Severe 8 (4.0) 4 (4.0)
AERD 30 (14.9) 17 (17.2)
Smoking
Never smoked 130 (64.7) 69 (69.7)
Former smoker 65 (32.3) 24 (24.2)
Current smoker 6 (3.0) 6 (6.1)
Symptomatic findings
Nasal obstruction/congestion score ≥2 on 5 of 7 days, n (%) 201 (100) 99 (100)
Nasal obstruction/congestion score (scale 0 to 3) 2.4 ± 0.5 2.4 ± 0.5
Decreased sense of smell score (scale 0 to 5) 4.1 ± 1.4 4.1 ± 1.4
Facial pain/pressure score (scale 0 to 5) 1.9 ± 1.4 2.2 ± 1.4
Endoscopic findings by an independent reviewer
Polyp grade ≥2 on each side (scale 0 to 4), n (%) 201 (100) 99 (100)
Bilateral polyp grade (scale 0 to 8) 5.95 ± 0.94 5.87 ± 1.00

*Values are means ± SD or as indicated. Only incidence of asthma (mainly mild) differed significantly between the groups (p = 0.0336).

aMedical history based on physician diagnosis as recorded in patient medical records.

AERD = aspirin exacerbated respiratory disease; CRS = chronic rhinosinusitis; ESS = endoscopic sinus surgery; INCS = intranasal corticosteroid sprays; SD = standard deviation.